Evidence map›Paper›PMID 39926616›Full record

ReviewNon-coding RNA research2025

Long non-coding RNA transcripts in

Mahalakshmi Vijayaraghavan, Shrikanth S Gadad, Subramanian Dhandayuthapani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Non-coding RNA research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. MALAT1-miR-20b-5p-P2RX7 Axis RegulatesVeterinary sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahalakshmi VijayaraghavanCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Texas-79905, USA.
Shrikanth S GadadCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Texas-79905, USA.
Subramanian DhandayuthapaniCenter of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, Texas-79905, USA.

Funding

A Novel Hyper-Immunogenic Low Virulent BCG vaccine against TuberculosisR01AI175837 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI SUBRAMANIAN DHANDAYUTHAPANI · 2023 to 2026
$2.0M
A novel quadruple knockout MTb vaccine against tuberculosis (Supplement Resubmission)R15AI156647 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER AT EL PASO · PI DHANDAYUTHAPANI, SUBRAMANIAN · 2021 to 2023
$626k
Analysis of Divergent Transcripts in Estrogen-Dependent SignalingR16GM149497 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Shrikanth Gadad · 2023 to 2026
$620k
NIAID NIH HHS R01 AI175837NIAID NIH HHS R15 AI156647NIGMS NIH HHS R16 GM149497
6 · The paper itself

Abstract

Tuberculosis (TB) persists as a significant health threat, affecting millions of people all over the world. Despite years of control measures, the elimination of TB has become a difficult task as morbidity and mortality rates remain unaffected for several years. Developing new diagnostics and therapeutics is paramount to keeping TB under control. However, it largely depends upon understanding the pathogenic mechanisms of

Indexed as

Host-mtb interactionsImmune responselncRNAsMacrophagesMycobacterium tuberculosisSurvival strategies

Identifiers

PMID39926616
PMCPMC11803167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.